

INJECTABLE FORMULATIONS CONTAINING SUCCINATE

ABSTRACT OF THE DISCLOSURE

- 5 The invention is directed to formulations of a pharmaceutically active agent
for *in vivo* use. The formulations to which the invention is directed are designed to
minimize the pain associated with components in injectable formulations, other than
the pharmaceutically active agent. The invention is particularly directed to buffers
that provide for minimum pain upon injection. Insulin-like growth factor I (IGF-I) is
10 a preferred pharmaceutically active agent.

09285429 "040209
662040" 62458250